Biochemical and Biophysical Research Communications
Volume 108, Issue 4, 29 October 1982, Pages 1434-1440
β-adrenergic receptor induction in HeLa cells: Synergistic effect of 5-azacytidine and butyrate
References (20)
Biochem. Pharmac.
(1976)- et al.
Cell
(1975) - et al.
J. Biol. Chem.
(1981) - et al.
Cell
(1980) Cell
(1982)- et al.
J. Biol. Chem.
(1982) - et al.
Cell
(1981) - et al.
Cell
(1981) - et al.
Exp. Cell Res.
(1976) - et al.
Biochim. Biophys. Acta
(1978)
There are more references available in the full text version of this article.
Cited by (31)
Epigenetics in diagnosis, prognosis and therapy: Therapies targeting the epigenome
2020, Epigenetics and Reproductive HealthEfficacy of combined epigenetic therapies
2015, Drug Discovery in Cancer EpigeneticsKeynote review: Chromatin control and cancer-drug discovery: Realizing the promise
2006, Drug Discovery TodayCitation Excerpt :Drugs that inhibit DNA methyltransferase activity, such as 5-azacytidine and decitabine, reactivate methylation-dependent silenced genes in tumours and some of these agents have been evaluated in clinical trials [122]. Reports vary on their clinical activity, both as stand-alone agents and combination therapies [60,129–133]. Toxicity is a long-standing concern and, therefore, recent advances have focused on less toxic compounds with demethylating activity [134,135].
Selective hypermethylation of transcribed nucleosomal DNA by sodium butyrate
1994, Experimental Cell Research
Copyright © 1982 Published by Elsevier Inc.